Guideline of guidelines: non-muscle-invasive bladder cancer.
Guideline of guidelines: non-muscle-invasive bladder cancer.
复制标题
DOI：
10.1111/bju.13760
复制
发表时间：
2017-03
影响因子：
4.5
通讯作者：
Lotan Y
中科院分区：
文献类型：
--
作者：
Woldu SL;Bagrodia A;Lotan Y
非肌层浸润性膀胱癌（NMIBC）代表了绝大多数膀胱癌诊断，但该定义代表了一系列疾病，其临床病程可变，具有显著的复发风险和进展潜力。管理包括膀胱镜监测和膀胱内治疗的风险适应策略，目的是在安全的情况下保留膀胱。存在多种组织指南来帮助从业者管理这种复杂的疾病过程，但是据报道，不执业泌尿科医生的管理原则的遵守率很低。我们回顾了NMIBC的四个主要组织指南：美国泌尿外科协会（AUA）/泌尿肿瘤学会（SUO），欧洲泌尿外科协会（EAU），国家综合癌症网络（NCCN）和国家健康与护理卓越研究所（NICE）。
Non-muscle invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, however this definition represents a spectrum of disease with a variable clinical course notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with a goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, however adherence to management principles amongt practicing urologists is reportedly low. We review four major organizational guidelines on NMIBC: American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE).